• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Itamar Medical Ltd.

    12/16/21 8:41:20 AM ET
    $ITMR
    Medical/Dental Instruments
    Health Care
    Get the next $ITMR alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-38775
    Issuer: Itamar Medical Ltd.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 9 Halamish Street, PO Box 3579
    Caesarea ISRAEL 3088900
    Telephone number: + 972 4 617-7000
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    American Depository Shares
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2021-12-16 By Tara Petta EVP
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ITMR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ITMR

    DatePrice TargetRatingAnalyst
    9/20/2021$30.00 → $31.00Outperform → Market Perform
    SVB Leerink
    9/15/2021$33.85Buy → Neutral
    Ladenburg Thalmann
    9/14/2021$36.00 → $31.00Buy → Neutral
    HC Wainwright & Co.
    9/14/2021$30.00 → $31.00Outperform → Market Perform
    Cowen & Co.
    More analyst ratings

    $ITMR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Itamar Medical Reports Third Quarter 2021 Financial Results

      - Revenues Increased 23% Year-over-Year to $13.6 Million - - U.S. WatchPAT™ Revenues Increased 27% Year-over-Year to $11.3 Million - CAESAREA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the third quarter of 2021. "Third quarter results represent the strong traction our WatchPAT™ platform technology has gained entering the second half of 2021. Growth in the U.S. continues to outpace our overall growth on top of expanding adoption in the markets we serve thr

      11/18/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors

      CAESAREA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Marga Ortigas-Wedekind to its Board of Directors. Ms. Ortigas-Wedekind brings more than 30 years of medical technology and digital health experience including leadership roles in commercial and strategic marketing. She is currently the Chief Commercial Strategy Officer for Fogarty Innovation, a nonprofit organization in the medical technology space. In this role she is responsible for delivering commercial strategy gu

      8/12/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Reports Second Quarter 2021 Financial Results

      - Revenues Increased 41% Year-over-Year to $12.6 Million - - U.S. WatchPATTM Revenues Increased 53% Year-over-Year to $10.1 Million - - Raised Full Year 2021 Revenue Guidance to a Range of $53 Million to $54 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the second quarter of 2021. "Our second quarter results demonstrated further growth as our WatchPAT™ technol

      8/10/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Itamar Medical Ltd. (Amendment)

      SC 13G/A - Itamar Medical Ltd. (0001613170) (Subject)

      10/4/21 6:02:57 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Itamar Medical Ltd. (Amendment)

      SC 13G/A - Itamar Medical Ltd. (0001613170) (Subject)

      6/17/21 11:07:03 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Itamar Medical Ltd. (0001613170) (Subject)

      2/16/21 6:35:46 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Financials

    Live finance-specific insights

    See more
    • Itamar Medical Reports Third Quarter 2021 Financial Results

      - Revenues Increased 23% Year-over-Year to $13.6 Million - - U.S. WatchPAT™ Revenues Increased 27% Year-over-Year to $11.3 Million - CAESAREA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the third quarter of 2021. "Third quarter results represent the strong traction our WatchPAT™ platform technology has gained entering the second half of 2021. Growth in the U.S. continues to outpace our overall growth on top of expanding adoption in the markets we serve thr

      11/18/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Reports Second Quarter 2021 Financial Results

      - Revenues Increased 41% Year-over-Year to $12.6 Million - - U.S. WatchPATTM Revenues Increased 53% Year-over-Year to $10.1 Million - - Raised Full Year 2021 Revenue Guidance to a Range of $53 Million to $54 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the second quarter of 2021. "Our second quarter results demonstrated further growth as our WatchPAT™ technol

      8/10/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical to Report Second Quarter Financial Results and Host Conference Call on Tuesday, August 10, 2021

      CAESAREA, Israel, July 28, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced today that it will report its financial results for the second quarter 2021 before the U.S. market opens on Tuesday, August 10, 2021. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update. The call will be hosted by Gilad Glick, President and CEO, and Shy Basson, CFO. To listen live via webcast, please visit https://edge.media-server.com/mm

      7/28/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    SEC Filings

    See more
    • SEC Form 15-12B filed by Itamar Medical Ltd.

      15-12B - Itamar Medical Ltd. (0001613170) (Filer)

      12/27/21 6:02:01 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Itamar Medical Ltd.

      EFFECT - Itamar Medical Ltd. (0001613170) (Filer)

      12/27/21 12:15:19 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Itamar Medical Ltd.

      EFFECT - Itamar Medical Ltd. (0001613170) (Filer)

      12/27/21 12:15:09 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Itamar Medical downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Itamar Medical from Outperform to Market Perform and set a new price target of $31.00 from $30.00 previously

      9/20/21 6:33:53 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical downgraded by Ladenburg Thalmann with a new price target

      Ladenburg Thalmann downgraded Itamar Medical from Buy to Neutral and set a new price target of $33.85

      9/15/21 7:36:23 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Itamar Medical from Buy to Neutral and set a new price target of $31.00 from $36.00 previously

      9/14/21 6:31:39 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Leadership Updates

    Live Leadership Updates

    See more
    • Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors

      CAESAREA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Marga Ortigas-Wedekind to its Board of Directors. Ms. Ortigas-Wedekind brings more than 30 years of medical technology and digital health experience including leadership roles in commercial and strategic marketing. She is currently the Chief Commercial Strategy Officer for Fogarty Innovation, a nonprofit organization in the medical technology space. In this role she is responsible for delivering commercial strategy gu

      8/12/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Appoints Brad Fluegel to its Board of Directors

      CAESAREA, Israel, May 24, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Brad Fluegel to its Board of Directors. Mr. Fluegel's vast experience includes wide ranging leadership roles and 25+ years in the healthcare sector, primarily in strategy and business development. Most recently, Mr. Fluegel was Senior Vice President, Chief Healthcare Commercial Market Development Officer for Walgreens Co. In this role he was responsible for driving all commercial healthcare activities, including sales

      5/24/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care